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Available online xxxxObjective: Our aim was to determine the association between admission glucose level and short-term outcome
and extent of coronary artery occlusion in non-diabetic patientswith ST segment elevationmyocardial infarction
(STEMI).
Methods: 250 consecutive patients were included in this study without known diabetes mellitus admitted with
STEMI. Both glucose and HbA1c were measured on admission. All included patients had hemoglobin A (1c)
less than 6.5%. In-hospital and 3 months' major cardiac events MACE (mortality, heart failure, arrhythmias, car-
diogenic shock and recurrent ischemia) were documented. Theywere classiﬁed into two groups according to the
admission mean glucose level (group A with glucose level ≥ 160± 52mg/dl and group B included those glucose
level b 160 ± 52 mg/dl).
Results: Cardiac events were signiﬁcantly higher in group A versus group-B (P b 0.001). In-hospital and 3-month
mortality was higher in group-A than group-B patients (p b 0.01). Elevated admission glucose was associated
with larger infarct size (P b 0.002). The prevalence of coronary lesions and the multi-vessels disease was signif-
icantly higher in group-A versus group-B patients (P b 0.01). After multivariate analysis, glucose level was inde-
pendently associated with short-term mortality, and MACE (OR = 6.9; P b 0.03 and 2.4; P b 0.02, respectively).
ROC analysis showed that the admission blood glucose level of 160 mg/dl is an independent cut-off value
(AUC = 0.68; p b 0.001) in prediction of outcome of non-diabetic patients presented with STEMI.
Conclusions: In non-diabetic patients presented with STEMI, elevated admission glucose level was associated
with adverse outcome and more severe multi-vessel coronary lesions. The cut-off value was N160 mg/dl and
was considered an independent factor in prediction of outcome of non-diabetics presented with SEMI. Measure-
ment of admission blood glucose level enables identiﬁcation of this high-risk group for aggressive secondary risk
prevention.
© 2016 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Mortality1. Introduction
There are several well established risk factors for cardiovascular
disease such as family history, increased age, smoking, hypertension,
diabetes mellitus, dyslipidemia, obesity, overweight and physical
inactivity. But whether there are other risk factors? That will always
be a subject for researchers. In patients with acutemyocardial infarction
(AMI), stress hyperglycemia can commonly be observed. An association
between hyperglycemia and increased risk of mortality and poor prog-
nosis after AMI was well noted in patients with or without diabetes;
poor outcomes of patients with AMI may be related to hyperglycemia
[1].is an open access article under the CMany of critical illnesses are commonly complicated by hyperglyce-
mia caused by of stress and inﬂammatorymediators. Severity of disease
is one of the main risk factors for development of hyperglycemia, but
not all severely ill develop hyperglycemia and some do even in mild
disease [2].
Hyperglycemia at the time of hospital admission was associated
with shorter survival after acute myocardial infarction in patients both
with and without diabetes mellitus. It is not fully understood whether
this is due to the acute development of stress hyperglycemia or to the
quality of long-term metabolic control before the event. Moreover, the
mechanisms by which hyperglycemia affects survival are largely un-
known [3].
Acute hyperglycemia in AMI patients without known diabetes
mellitus was independently associated with larger infarct size and
higher long-termmortality rates after AMI [4]. Impaired micro vascularC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Comparison between group-A and group-B regarding demographic data.
Item Group A
(N = 130)
Group B
(N = 120)
P value Signiﬁcance
Age 59.7 ± 6.6 58 ± 5.75 0.08 Insigniﬁcant
M: F ratio 95/35
(70%/30%)
89/31
(78%/22%)
0.832 Insigniﬁcant
No. % No. %
Hypertension 39 30 38 31.5 0.839 Insigniﬁcant
Smoking 41 31.5 40 33.3 0.673 Insigniﬁcant
History of dyslipidemia 32 24.5 29 24.1 0.822 Insigniﬁcant
Family history of CAD 33 27.4 28 23.3 0.532 Insigniﬁcant
History of previous MI 8 6.6 7 5.1 0.727 Insigniﬁcant
M:F ratio = Male to female ratio.
CAD = coronary artery disease.
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Fig. 2. Showing laboratory characteristics among patients in the study, it shows a highly
signiﬁcant difference between group A & group B as regards mean troponin-I.
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farct size and worse functional recovery [5].
2. Aim of the work
The objective of this study is to evaluate the impact of admission
blood glucose level in non-diabetic patients presented with STEMI on
the occurrence ofMACE (mortality, heart failure, recurrent ischemia, ar-
rhythmias and cardiogenic shock) and on the extent of coronary artery
occlusion in an attempt to assess the predictive value of admission
blood glucose level on the outcome of non-diabetic patientswith STEMI.
3. Subjects and methods
This study included 250 consecutive patients presented with acute
ST elevation myocardial infarction, from December 2013 to August
2015. All of them were non-diabetic conﬁrmed by HbA1c level (less
than 6.5%). All were admitted within 12 h of the onset of STMI.
Venous blood was collected immediately upon hospital arrival,
before starting speciﬁc treatment such as revascularization (i.e.
thrombolysis or primary intervention). Blood chemistry measurement
(glucose, glycosylated hemoglobin, creatinine and lipid proﬁle) and
troponin I and CPK and CK-MB levels were conducted in our hospital
central laboratory. Plasma glucose level was measured using glucose
oxidase method. HbA1c level was considered abnormal when it was
N6.5% [6]. The mean blood glucose level on admission was (160 ±
52mg/dl) and the glycosylated hemoglobin (HbA1c) was 5.38 ± 0.56%.
The patients were classiﬁed into 2 groups according to their mean
blood glucose level: Group (A), included 130 patients with mean
blood glucose level ≥ 160 ± 52 mg/dl and group (B), included 120
with mean blood glucose level ≤ 160 ± 52 mg/dl.
3.1. Exclusion criteria
Patients with known diabetes mellitus either from history or by
HbA1c (≥6.5%), patients admitted after 12 h of the onset of STEMI,0
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Fig. 1. Laboratory characteristics among patients in the study, it shows a highly signiﬁcant
difference between group A & group B as regards mean CK MB.patients with end stage disease that might affect the prognosis
e.g., malignancy, end-stage chronic kidney disease, and advanced liver
disease.
A written consent was taken from all patients after explaining the
study, its importance and their role in completing it.
The diagnosis of STEMI was determined as chest pain lasting more
than 20 min, electrocardiography examination revealed ST segment
elevation and elevated cardiac enzyme (i.e. troponin I ≥ 0.6 ng/mL) [7].3.2. Echocardiography
To determine left ventricular function, an echocardiography exami-
nation was performed. It was conducted within hospitalization course
and after three months of discharge. M-mode and two-dimensional
echocardiography as well as Doppler echocardiography were
performed. Left ventricular systolic function was determined based on
the value of left ventricular ejection fraction (LVEF). Normal LVEF is
≥50%. Accordingly, we used cut-off point of LVEF 50% to determine left
ventricular systolic dysfunction.3.3. Diagnostic coronary angiography
A diagnostic coronary angiography was done to all patients in the
Cathlab unit of the cardiology department of Zagazig University within
hospital course fromwhich data is collected about coronary artery affec-
tion, lesions and their extension, number of affected vessels, number of
signiﬁcant lesions, which vessel is affected and the choice of manage-
ment decided according to the AHA/ACC 1993 guidelines and its
revision 2001 [8].3.4. Follow up
It was done during hospital stay and for threemonths after the onset
of STEMI for major cardiac complications as heart failure, arrhythmias,
recurrent ischemia, cardiogenic shock and death.Table 2
Prevalence of complications during the follow-up period among group-A patients versus
group-B patients.
Item Group A
(No. = 130)
Group B
(No. = 120)
P value
No. % No. %
Death 8 6.1% 2 1.7% b0.01
Heart failure 47 36% 19 16% b0.01
Arrhythmias 49 38% 16 13.3% b0.01
Cardiogenic shock 10 7.6% 4 3.3% b0.02
Recurrent ischemia 35 17% 10 8.2% b0.02
Table 3
Angiographic results in group-A patients versus group-B patients.
Item Group A
(NO of lesions = 397)
Group B
(NO of lesions = 226)
P value
NO. of patients % NO. of patients %
• 1–2 signiﬁcant lesions 22 16.9% 65 54.1% b0.001
• Three signiﬁcant lesions 38 29.2% 24 20% b0.05
• N3 signiﬁcant lesions 63 48.5% 17 14.1% b0.001
• Non-signiﬁcant lesions (b50%) 7 5.4% 14 11.8% b0.05
Signiﬁcant lesion means N50% stenosis in left main coronary artery and N70% lesion in other major epicardial coronary artery.
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All results were tabulated and statistical analysis was performed
using IBM compatible PC computer and bymeans of statistical software
package namely (SPSS) Version 10.
The correlation between continuous variables was tested using
Spearman test.
Logistic Regression analysis was used to assess the association
between admission blood glucose and other predictors.
Predictors signiﬁcantly associated with major cardiac events then
entered into multivariable analysis with stepwise multivariate logistic
regression method to analyze the independent association.
Receiver operating characteristic curve (ROC) was used to test the
mean blood glucose level (≥160 mg/dl) in prediction of MACE in
non-diabetic patients with STEMI.
5. Results
The demographic data are represented in Table 1. Both groups were
comparable regarding age, sex, hypertension, smoking, dyslipidemia
and family history of coronary artery disease. CK-MB was signiﬁcantly
higher in group-A versus group-B (192 ± 114.7 versus 114.7 ± 43.75;
P b 0.001); Troponin-I was 5 ± 2.59 in group-A versus 2.2 ± 0.77 in
group-B (P b 0.001; Figs.1 and 2).
The prevalence of MACE (death; heart failure; arrhythmias; cardio-
genic shock and recurrent ischemic attacks) was signiﬁcantly higher
in group-A patients compared with group-B patients (Table 2).
Patients with an admission blood glucose ≥160 ± 52 mg/dl had
signiﬁcantly higher incidence of death as compared with those with
on admission blood glucose b160 ± 52 mg/dl (6.1% versus 1.7%,
P b 0.03).
Left ventricular systolic dysfunction developed more frequently in
patients group-A than those in group-B (36% versus 16%, P b 0.01)
(Table 2). Furthermore, the higher the blood glucose value, the
lower the left ventricular ejection fraction (Spearman correlation:
r =−0.33, P = 0.001; Table 4).
Patients with on admission blood glucose ≥160 ± 52 mg/dl had
signiﬁcantly higher proportion of rhythm disorders as compared with
those with on admission blood glucose b160 ± 52 mg/dl (38% versus
13.3%, P b 0.01).Table 4
Correlation between on admission blood glucose level with other variables.
Variables r P value
Age −0.09 0.31
Hypertension −0.07 0.48
Total cholesterol −0.18 0.24
LDL cholesterol −0.16 0.08
HDL cholesterol 0.11 0.59
Triglyceride −0.07 0.72
CK-MB 0.32 b0.001
Troponin-I 0.36 b0.001
LV EF% −0.33 b0.001
LVEF means left ventricular ejection fraction.The proportion of cardiogenic shock was signiﬁcantly higher in
group-A patients as compared to group-B patients (7.6% versus 3.3%,
P b 0.02).
Moreover 17% in group-A suffered from recurrent ischemic attacks
and requiring hospital re-admission versus 8.2% in group-B (P b 0.02).
Table 3 shows the angiographic data of both groups; the total num-
ber of coronary lesions and the multi-vessels disease were signiﬁcantly
higher in group-A patients versus group-B patients. The results showed
that the admission glucose level was signiﬁcantly correlated with car-
diac enzymes (r = 0.32; P b 0.001 for CK-MB and r = 0.36; P b 0.001
for troponin-I)
Table 4 shows logistic regression analysis showed that the admission
blood glucose level was signiﬁcantly independent risk factor for cardiac
events in patients presented with STEMI.
Table 5 shows logistic regression analysis of admission blood glucose
level as a risk factor for cardiac events in non-patients with STEMI with
signiﬁcant increase of cardiac events in group-A than group-B (CHF
(P b 0.05), post infarction angina (P b 0.05), arrhythmia (P b 0.05) and
cardiogenic shock (P b 0.05) with more cardiac mortality (P b 0.05)).
Table 6 shows stepwise multivariate logistic regression analysis, ad-
justed with diagnosis of STEMI, age; hypertension; dyslipidemia and
family history of CAD revealed that on admission high blood glucose
was independently associated with short-term course cardiac events
(Odds ratio 2.3, 95% conﬁdence interval: 1.1–4.9, P= 0.03) andmortal-
ity (Odds ratio = 6.9, 95% conﬁdence interval: 1.2–38.6, P = 0.03)
In Table 7 and Fig. 3, ROC analysis showed that the mean value
(160 mg/dl) of the admission blood glucose is an independent and
signiﬁcant predictor of MACE in non-diabetic patients with STEMI
(AUC = 0.68; P b 0.001) with sensitivity (86%), speciﬁcity (93%),
positive predictive value (89%) and negative predictive value (82%).6. Discussion
This study demonstrated that stress hyperglycemia on admission in
the absence of diabetes mellitus is a signiﬁcant predictor of adverse
outcome and the extent and severity of coronary artery lesions in
non-diabetic patients presenting with STEMI. However, level of choles-
terol, LDL, history of hypertension, smoking and family history of coro-
nary artery diseasewas not signiﬁcant predictors of adverse outcome. In
the current study, the incidence of stress hyperglycemia was 52%, based
on our classiﬁcation of patients according to their on admission blood
glucose level (mean blood glucose of 160 ± 52 mg/dl).Table 5
Logistic regression analysis of admission blood glucose level as a risk factor for cardiac
events in non-patients with STEMI.
Variable OR P value
CHF 1.319 b0.05
Post-infarction angina 1.363 b0.05
Arrhythmia 1.362 b0.05
Cardiogenic shock 1.095 b0.05
Cardiac death 1.256 b0.05
CHF: congestive heart failure.
Table 6
Stepwise multi-variate logistic regression analysis for predictors of major cardiac events
and mortality.
Variables Events Mortality
OR
(95% CI)
P value OR
(95% CI)
P value
Blood glucose 2.4 (0.9–5.2) 0.02 6.9 (1.1–12.9) 0.03
Age 1.02(0.5–1.1) 0.12 0.96(0.3–1.3) 0.31
History of smoking 0.8(0.5–1.2) 0.22 0.92(0.3–1.5) 0.09
Total cholesterol 0.9(0.6–1.1) 0.09 0.99 (0.7–1.1) 0.07
Hypertension 0.7(0.5–1.7) 0.38 0.9(0.4–3.8) 0.49
Fig. 3. Receiver operating characteristic (ROC) curves shows (AUC= 0.68; P b 0.001).
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blood glucose level for classiﬁcation of non-diabetic patientswith STEMI
and we reported that admission blood glucose of ≥160 mg/dl can be
considered a cute-off value in prediction of MACE and the extent of
coronary artery lesions in non-diabetic patients presented with STEMI.
Myocardial infarction is a stressful condition that causes elevation of
stress hormones and subsequent elevation of blood glucose [9]. There is
no currently consensus about the precise glucose value (or range of
values) for the threshold of stress hyperglycemia, in the matter of fact;
there is no currently consensus about the best method to measure
blood glucose in stress hyperglycemia [10].
Studies differed in the determination of the threshold for stress
hyperglycemia, Capes et al. [11] used the value of 110 mg/dL as the
threshold for hyperglycemia in non-diabetic patients and Marfella
et al. [12] used the value of 126 mg/dL. While others like Maarten de
Mulder et al. [13] took the value of 140mg/dL as the threshold. Goldberg
et al. [14] supposed that instead of threshold, multiple glucose results
must be analyzed; several measurements exist, such as mean glucose
level, time averaged glucose level, hyperglycemia index and patient
day glucose level.
The current study showed that there was a positive correlation ob-
served between glucose level and CK-MB and troponin I level. This indi-
cated that the elevated blood glucose level was in conjunction with the
severity of myocardial damage.
Marfella et al. [12] found that the patients with stress hyperglycemia
were found to have higher values of CK total, CK-MB and Troponin I.
[15–17] and reported that total CPK was higher and the incidence of
larger infarcts was signiﬁcantly greater in patients with high than in
patients with low admission glucose.
Anantharaman R et al. found that high admission blood glucose as-
sociatedwithmore LV systolic dysfunction during follow-up. In addition
recurrent anginal attacks, arrhythmias and cardiogenic shock were also
more frequent among those patients. This may be related to the stress
response that occurred early and lasted for several days, with subse-
quent release of more catecholamine and corticosteroids during which
increased gluconeogenesis and lipolysis lead to increased circulating
glucose, free-fatty acids and lactic acid [18]. These metabolic distur-
bances change metabolic substrate for myocardium which became
intoxicated [19].
The current study showed that high blood glucose on admission in-
dependently associated with short term mortality. Previous reports
showed that non-diabetic patientswith high blood glucose at admissionTable 7
Cut-off values, sensitivity, speciﬁcity, positive predictive value, and negative predictive
value of admission blood glucose ≥160 mg/dl.
Admission blood glucose ≥160 mg/dl
Sensitivity 86%
Speciﬁcity 93%
Positive predictive value 89%
Negative predictive value 82%
AUC 0.68
P value b0.001
AUC = Area under the curve.had similar increased mortality rate to those with established diabetes
mellitus [20].
The prevalence of multi-vessels diseases and the number of signiﬁ-
cant coronary lesions was signiﬁcantly higher in patients with higher
admission glucose level in patients with STEMI.7. Conclusion
On admission random blood glucose had a signiﬁcant impact in pre-
diction of major cardiac events in non-diabetic patients presented by
STEMI. In addition the on admission blood glucose level has a signiﬁcant
correlation with the degree and the extent of coronary artery lesions in
those patients. The mean value of 160 mg/dl can be considered a good
cut-off value for the prediction of MACE in non-diabetic patients pre-
sented with STEMI. So Serum random blood glucose on admission
could be independent risk stratiﬁcation in non-diabetic patients pre-
sented with STEMI.References
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